pharma&

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Data at ADA 2026

GLP-1 · 5 min

Hengrui Pharma and Kailera Therapeutics presented clinical data for oral ribupatide (HRS9531) at the ADA 2026 conference. The Phase 2 trial showed positive weight loss results, and the partners plan to advance the asset into two new trials.

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.